Chronic mast cell leukemia

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

Regulatory Watchboard

8 events

Mar 2026A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Ascentage Pharma Group Inc. — PHASE1

TrialNOT YET RECRUITING

Aug 2025The Effects of Intra-articular and Peri-articular Platelet-rich Plasma (PRP) Injections ın Chronic Knee Osteoarthritis

Ankara City Hospital Bilkent — NA

TrialRECRUITING

Sep 2023Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

iOMEDICO AG

TrialRECRUITING

Mar 2023Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

National Heart, Lung, and Blood Institute (NHLBI)

TrialRECRUITING

Jan 2023Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Northwell Health — NA

TrialRECRUITING

May 2020CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Medical College of Wisconsin — PHASE1, PHASE2

TrialRECRUITING

Feb 2019Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Memorial Sloan Kettering Cancer Center — PHASE2

TrialRECRUITING

Jun 2017A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

2

Copay cards

Copay Assistance2

Ketalar

Par

OpenContact for details

Krystexxa

Amgen

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Krystexxa

(pegloticase)Orphan drugstandard

Horizon Therapeutics Ireland DAC

Uric Acid-specific Enzyme [EPC]

12.1 Mechanism of Action KRYSTEXXA is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the...

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Chronic mast cell leukemia.
Search all trials →

Search clinical trials for Chronic mast cell leukemia →

Recent News & Research

No recent news articles indexed yet for Chronic mast cell leukemia.
Search PubMed for Chronic mast cell leukemia →

Browse all Chronic mast cell leukemia news →

Specialist Network

Top 6 by expertise

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

📍 SEATTLE, WA

Score 2917 trials

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Score 2111 trials

Jorge Cortes, MD

UT MD Anderson Cancer Center

Score 1917 trials

Kyoo H. Lee, MD

Asan Medical Center

Score 138 trials

Maryam Fouladi, MD

COG Phase I Consortium

📍 COLUMBUS, OH

Score 127 trials2 pubs

Marie Bleakley, MD

Fred Hutch/University of Washington Cancer Consortium

📍 SEATTLE, WA

Score 124 trials

View all Chronic mast cell leukemia specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles